Intralesional Administration of the CD47 Antagonist TTI-621 (SIRP{alpha}Fc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Interim Results of a Multicenter Phase I Trial

ConclusionsPreliminary data from this ongoing study indicate that IL TTI-621 administration is well-tolerated and has single agent activity in heavily pre-treated MF/SS patients across various disease stages. The rapid responses observed occurred in both injected and non-injected lesions indicating a local-regional effect with initial evidence of distant abscopal or systemic effects. Enrollment in this study is continuing to evaluate the impact of weekly maintenance dosing and further characterize the systemic effect and durability of responses.DisclosuresQuerfeld: Kyowa: Membership on an entity's Board of Directors or advisory committees; Acelion: Membership on an entity's Board of Directors or advisory committees; Bioniz: Membership on an entity's Board of Directors or advisory committees; Medivir: Membership on an entity's Board of Directors or advisory committees; Trillium Therapeutics: Membership on an entity's Board of Directors or advisory committees. Thompson: Trillium Therapeutics: Research Funding. Taylor: Trillium Therapeutics: Research Funding. Johnson: Trillium Therapeutics: Employment. Catalano: Trillium Therapeutics: Employment. Petrova: Trillium Therapeutics: Employment. Thompson: Trillium Therapeutics: Employment. Uger: Trillium Therapeutics: Employment. Shou: Trillium Therapeutics: Employment. Akilov: Kyowa Kirin: Consultancy; Pfizer: Research Funding; Seattle Genetics: Consultancy; Trillium Therapeutics: Research Funding; Actelion Pharmaceuticals: Consultan...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I Source Type: research